Carrier‐Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery
John A. Quinlan(National Cancer Institute), Huang‐Chiao Huang(University of Maryland, Baltimore), Idrisa Rahman(National Institutes of Health), Brandon Gaitan(University of Maryland, College Park), Michael M. Gottesman(National Cancer Institute), Nina P. Connolly(University of Maryland, Baltimore), A Gaur(University of Maryland, College Park), Robert W. Robey(National Institutes of Health), Baktiar Karim(Frederick National Laboratory for Cancer Research), Carla Arnau del Valle(University of Maryland, College Park), Jillian Stabile(University of Maryland, College Park), Graeme F. Woodworth(West Virginia University), Kaylin Baumiller(University of Maryland, College Park), Payal Srivastava(University of Maryland, College Park), Wen‐An Chiou(Implant Sciences (United States)), Collin T. Inglut(National Institutes of Health)
Cited by 32
Related Papers
Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes
|Pharmacological Reviews|2012|968
Inorganic nanoparticles for cancer imaging and therapy
|Journal of Controlled Release|2011|599
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
|Cancer Research|2008|385
Immunological and Toxicological Considerations for the Design of Liposomes
|Nanomaterials|2020|357
Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting
|Journal of Nanobiotechnology|2020|327